Mirikizumab
Mirikizumab is an experimental monoclonal antibody designed for the treatment of psoriasis, ulcerative colitis, and Crohn's disease. It is developed by Eli Lilly and Company.
Mechanism of action[edit | edit source]
Mirikizumab works by targeting interleukin 23, a molecule that plays a key role in inflammatory processes of the immune system and is thought to be linked to a number of chronic immune diseases, including psoriasis and ulcerative colitis.
Clinical trials[edit | edit source]
Phase 2 trials for psoriasis showed promising results for mirikizumab. Most patients in the trial achieved significant skin clearance, with a clear or almost clear skin rating of 0/1 on the Psoriasis Area and Severity Index (PASI), and a 90% reduction in the PASI score (PASI 90).
Mirikizumab has also undergone Phase 2 trials for ulcerative colitis. Results indicated that the drug was well tolerated and met the primary endpoint of the study.
Development[edit | edit source]
The development of mirikizumab is being carried out by Eli Lilly and Company. The drug is currently in Phase 3 clinical trials.
See also[edit | edit source]
- List of investigational drugs
- Monoclonal antibodies (mAbs)
- Interleukin 23
- Psoriasis
- Ulcerative colitis
- Crohn's disease
Mirikizumab Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD